^
Association details:
| Biomarker: | FGF19 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | roblitinib (FGF401) (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
Published date:
11/25/2020
Excerpt:
Mice bearing high and low FGF19-expressing tumors were treated with FGF401 and/or vinorelbine, and the antitumor activity of both agents was assessed individually and in combination...FGF401 potently inhibited the growth of high FGF19-expressing HCC models regardless of FGF19 gene amplification...Our study suggests that a subset of patients with high FGF19-expressing HCC tumors could benefit from FGF401 or FGF401/vinorelbine treatment.
DOI:
10.1038/s12276-020-00524-4
Source:
Title:
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
Published date:
11/25/2020
Excerpt:
Mice bearing high and low FGF19-expressing tumors were treated with FGF401 and/or vinorelbine, and the antitumor activity of both agents was assessed individually and in combination...FGF401 potently inhibited the growth of high FGF19-expressing HCC models regardless of FGF19 gene amplification...Our study suggests that a subset of patients with high FGF19-expressing HCC tumors could benefit from FGF401 or FGF401/vinorelbine treatment.
Secondary therapy:
vinorelbine tartrate
DOI:
10.1038/s12276-020-00524-4
